15 aug: Ringkjøbing Landbobanks halvårsrapport for 1. halvår 2018
15 aug: William Demant Holding A/S: Halvårsrapport 2018
15-08-2018 03:37:00

Six-month interim report (Q2) 2018

Relateret indhold
12 nov - 
Aktier/tendens: Pilen peger opad for børsdagen
09 nov - 
Fredagens aktier: Klø til Chr. Hansen sendte C25 på wee..
09 nov - 
Aktier/middag: Chr. Hansen trækker C25 i rødt efter sto..
Relateret debat
12 nov - 
Ok, men din måde at formulere det på, lignede et citat ..
12 nov - 
Nej, gittekh. Det var helt bestemt ikke nogen fejl ved ..
12 nov - 
Søren Hansen, Sydbank var meget positiv på regnskabsdag..

Better than expected performance in Q2 (unaudited)

ALK’s financial performance in Q2 was better than expected and full-year outlook has been improved. The execution of ALK’s new growth strategy is on track, with good progress being made on the commercialisation of SLIT-tablets – these saw 36% growth globally – and the US launch of ODACTRA™ progressing as planned. The roll-out of ALK’s new Consumer Care division and the ongoing drive for improved efficiencies are also advancing better than expected.

Q2 2018 highlights:

  • Total revenue was DKK 715 million (691). Revenue growth was 5% in local currencies. Exchange rates reduced reported revenue growth by approximately 2 percentage points.   
  • Global SLIT-tablet sales grew by 36% to DKK 183 million (134).  
  • Global SCIT/SLIT-drops sales were down 3% to DKK 410 million (426). The decline was largely attributable to planned portfolio rationalisations and the ongoing negative effect of previous production capacity constraints.
  • Operating profit (EBITDA) of DKK 10 million (16) was ahead of ALK's expectations and benefitted from higher than expected sales and faster than anticipated capture of operational efficiencies and savings.
  • In the first half-year, total revenue was DKK 1,467 million (1,480) and operating profit was DKK 102 million (156).
  • In the first half-year, free cash flow was minus DKK 201 million (minus 533).

Progress on the four strategic priorities

  1. In North America, the roll-out of ACARIZAX®/ODACTRA™ continues, and in the key US market, the increase in new patients and prescribers is progressing according to plan and managed care coverage expands better than planned.
  2. Commercialisation of the tablet portfolio gained momentum, with the robust uptake of ACARIZAX® continuing following further new launches and approvals. Meanwhile, a regulatory filing for the tree tablet in Europe is imminent and CEDARCURE™ has now been launched by ALK’s partner in Japan.  
  3. Patient engagement and Consumer Care division activities are on track and ALK has seen encouraging growth in web traffic on its digital platforms. The consumer platform klarify.me has been launched in a beta version in its first market as an important first step towards expanding ALK’s overall presence in allergy.
  4. The drive to optimise and reallocate resources is delivering operational efficiencies. At the same time, output and inventories of SCIT and SLIT-drops have been normalised and robustness in Product Supply is improving and now stabilised. Work to trim the product portfolio continues.

Improved 2018 financial outlook

Full-year outlook has slightly improved compared with the Q1 report, which was released on 4 May 2018.

  • Full-year revenue is now projected to be more than DKK 2.8 billion (previously: more than DKK 2.7 billion).
  • Operating profit (EBITDA) is now expected at around DKK 50 million (previously around DKK 0), reflecting the better than expected performance in the first half-year and more clarity on market conditions in Southern Europe.
  • ALK will continue to invest significantly in the strategic transformation of the company in the second half-year.  
  • Free cash flow is now expected at around minus DKK 550 million or better (previously: minus DKK 600 million or better).

Hørsholm, 15 August 2018

ALK-Abelló A/S

Comparative figures for 2017 are shown in brackets. G

rowth rates are stated in local currencies, unless otherwise indicated

For further information, contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Jeppe Ilkjær, tel. +45 7877 4532, mobile +45 3050 2014

Today, ALK is hosting a conference call for analysts and investors at 1.30 p.m. (CEST) at which Management will review the financial results and the outlook. The conference call will be audio cast on https://ir.alk.net/. Participants for the audio cast are kindly requested to call in before 1.25 p.m. (CEST). Danish participants should call in on tel.

+45 7022 3500 and international participants should call in on tel. +44 (0) 20 7572 1187 or +1 646 722 4972.

Please use the Participant Pin Code: 95314096#. The conference call will also be webcast live on our website, where the related presentation will be made available shortly before the call begins.

Attachment

Primary Logo

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
12 nov
ALK-B
Nu kan jeg se, at du lægger præcis samme ordlyd på en kommentar til NKT. Jeg håber det er en fejl
1

Schouw/CEO: Arbejder på at imødegå effekten af højere råvarepriser

12-11-2018 15:37:16
Stigende råvarepriser og hård konkurrence har givet indtjeningsmæssig modvind for industrikonglomeratet Schouw & Co. i tredje kvartal, men udviklingen har ifølge selskabets direktør, Jens Bjerg Sørensen, dog været som ventet. Den kommende tid er fokus særligt rettet mod at optimere og effektivisere, efter at selskabet tidligere har gennemført store kapacitetsinvesteringer. - Tredje kvartal er gået..

William Demant fjerner variant af i øret-apparat - citat - NY

12-11-2018 13:59:53
William Demant Holding kan ikke længere tilbyde en variant af selskabets nye ITE-produkter (in the ear, red.) af Oticon Opn, der har både telespole og trådløs 2,4 GHz-teknologi.Kunderne skal nu vælge mellem en ITE-udgave med telespole eller 2,4 GHz-teknologi.Det skriver branchemediet Medwatch.Produktet blev ellers først lanceret for nylig og blev sammen med en stribe andre nye produkter præsentere..

NKT vinder ordre til en værdi af næsten 150 mio. kr.

12-11-2018 09:35:50
Den danske kabelproducent NKT skal udskifte højspændingsforbindelsen mellem Danmark og Sverige.Det bekræfter NKT i en meddelelse mandag morgen, hvor det også fremgår, at ordrens værdi i standard metalpriser lyder på 20 mio. euro, svarende til næsten 150 mio. danske kr.Ordren er vundet i et konsortium med Boskalis, der tidligere gik under navnet VBMS. Den indebærer projektering, produktion og insta..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Danske Bank/Kepler: Anbefaling og kursmål trækkes hver sin vej
2
Aktier/tendens: Pilen peger opad for børsdagen
3
NKT vinder ordre til en værdi af næsten 150 mio. kr.
4
Aktier: Sydbank og Rockwool kan erstatte Nordea og Bavarian i C25
5
Mandagens aktier: Simcorp blev straffet i generelt nervøst marked

Relaterede aktiekurser

ALK-Abelló B A/S 995,00 -6,8% Fald i aktiekurs

Køb- og salgssignaler

  • Trend
  • Pengemaskinen

Copyright Berlingske Media 2018  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
13. november 2018 01:46:06
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20181109.5 - EUROWEB7 - 2018-11-13 01:46:06 - 2018-11-13 01:46:06 - 1 - Website: OKAY